Copeland Capital Management’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$924K Sell
4,742
-87
-2% -$18K 0.02% 133
2026
Q1
$1.08M Buy
4,829
+556
+13% +$139K 0.02% 129
2025
Q4
$1.03M Sell
4,273
-197
-4% -$50.4K 0.02% 129
2025
Q3
$1.22M Sell
4,470
-850
-16% -$232K 0.03% 128
2025
Q2
$1.37M Sell
5,320
-185
-3% -$44.1K 0.03% 121
2025
Q1
$1.23M Sell
5,505
-1,062
-16% -$248K 0.02% 119
2024
Q4
$1.5M Sell
6,567
-257
-4% -$61.9K 0.03% 119
2024
Q3
$1.67M Sell
6,824
-194
-3% -$43.4K 0.03% 122
2024
Q2
$1.34M Sell
7,018
-244
-3% -$49.5K 0.03% 122
2024
Q1
$1.44M Sell
7,262
-173
-2% -$31.7K 0.03% 120
2023
Q4
$1.28M Buy
7,435
+3,547
+91% +$545K 0.03% 115
2023
Q3
$575K Sell
3,888
-1,919
-33% -$347K 0.01% 128
2023
Q2
$1.27M Sell
5,807
-286
-5% -$63.7K 0.03% 119
2023
Q1
$1.33M Sell
6,093
-163
-3% -$35.4K 0.03% 116
2022
Q4
$1.3M Sell
6,256
-213
-3% -$46.8K 0.03% 120
2022
Q3
$1.41M Sell
6,469
-283
-4% -$64.4K 0.05% 117
2022
Q2
$1.42M Buy
6,752
+1,279
+23% +$272K 0.04% 119
2022
Q1
$1.33M Buy
5,473
+253
+5% +$61.2K 0.04% 121
2021
Q4
$1.36M Sell
5,220
-179
-3% -$46.4K 0.04% 125
2021
Q3
$1.42M Sell
5,399
-1,069
-17% -$292K 0.04% 122
2021
Q2
$1.59M Buy
6,468
+95
+1% +$20K 0.05% 121
2021
Q1
$1.24M Sell
6,373
-1,681
-21% -$337K 0.04% 125
2020
Q4
$1.71M Sell
8,054
-85,320
-91% -$17M 0.07% 113
2020
Q3
$16M Sell
93,374
-1,857
-2% -$343K 0.71% 59
2020
Q2
$18.3M Buy
95,231
+1,511
+2% +$247K 0.94% 44
2020
Q1
$13.8M Buy
93,720
+5,148
+6% +$820K 0.84% 52
2019
Q4
$13.7M Buy
88,572
+17,495
+25% +$2.52M 0.6% 60
2019
Q3
$9.6M Sell
71,077
-17,951
-20% -$2.35M 0.49% 66
2019
Q2
$10.9M Buy
89,028
+15,707
+21% +$1.74M 0.6% 58
2019
Q1
$7.62M Buy
73,321
+10,234
+16% +$1.06M 0.48% 65
2018
Q4
$7.18M Sell
63,087
-47,457
-43% -$5.08M 0.51% 70
2018
Q3
$12.8M Buy
110,544
+1,084
+1% +$119K 0.77% 65
2018
Q2
$11.3M Sell
109,460
-441
-0.4% -$44.6K 0.66% 70
2018
Q1
$10.8M Sell
109,901
-31,907
-23% -$3.02M 0.69% 70
2017
Q4
$12M Buy
141,808
+2,577
+2% +$213K 0.76% 62
2017
Q3
$10.7M Sell
139,231
-2,567
-2% -$196K 0.73% 61
2017
Q2
$11M Buy
141,798
+24,056
+20% +$1.72M 0.72% 63
2017
Q1
$8.52M Sell
117,742
-10,274
-8% -$710K 0.59% 76
2016
Q4
$7.94M Buy
128,016
+364
+0.3% +$22.3K 0.52% 76
2016
Q3
$8.27M Sell
127,652
-3,828
-3% -$255K 0.53% 80
2016
Q2
$8.31M Sell
131,480
-8,735
-6% -$515K 0.57% 67
2016
Q1
$8.11M Sell
140,215
-2,586
-2% -$146K 0.56% 76
2015
Q4
$7.67M Sell
142,801
-1,394
-1% -$78.6K 0.43% 86
2015
Q3
$7.35M Buy
144,195
+1,282
+0.9% +$69K 0.45% 83
2015
Q2
$8.06M Buy
142,913
+123,592
+640% +$7.8M 0.41% 96
2015
Q1
$1.39M Sell
19,321
-9,386
-33% -$610K 0.09% 114
2014
Q4
$1.61M Buy
28,707
+25,054
+686% +$1.31M 0.12% 113
2014
Q3
$180K Hold
3,653
0.02% 160
2014
Q2
$185K Buy
+3,653
New +$181K 0.02% 154

Other funds holding RMD

Copeland Capital Management's RMD Position: Q2 2026 in Review

Copeland Capital Management reduced its ResMed (RMD) stake by 1.8% in Q2 2026, selling an estimated $18K and leaving 4,742 shares worth $924K. The position accounts for 0.02% of the portfolio, ranked #133.

Copeland Capital Management first reported a position in RMD in Q2 2014 and has held it in 49 quarters since. The position peaked at $18.3M in Q2 2020. 882 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Copeland Capital Management held 4,742 shares of ResMed worth $924K as of Q2 2026.
  • Copeland Capital Management sold 87 ResMed shares in Q2 2026, an estimated $18K.
  • ResMed made up 0.02% of Copeland Capital Management's portfolio in Q2 2026, its #133 holding.
  • Copeland Capital Management first reported a position in ResMed in Q2 2014 and has held it in 49 quarters since.
  • Copeland Capital Management's ResMed position peaked at $18.3M in Q2 2020.
  • 882 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Copeland Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.